Last checked at 
(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.
----------
SMALL-CAP - WINNERS
----------
Capital & Regional PLC, up 7.8% at 57.77 pence, 12-month range 42p-67p. Shares in the shopping centre-focused real estate investment trust make strong gains. The stock is now in positive territory in the year-to-date, up 0.8%.
----------
abrdn European Logistics Income PLC, up 3.9% at 70.13 pence, 12-month range 62.33p-105p. The investment fund focusing on European logistics real estate says net asset value per share at June 30 falls to 108.3 euro cents from 111.2 cents at March 31. However, Troels Andersen, abrdn's lead fund manager, says the continental European logistics sector has "held up relatively well" despite headwinds of base rate rises and economic pressures. "The slowing capital value decline across the portfolio this quarter reflects improving investor sentiment... Indicators suggest that some regions may be starting to see the early stages of this reversal in sentiment with buying interest returning for well-placed logistics portfolios and the hoped-for early stages of recovery in values," he says.
----------
SMALL-CAP - LOSERS
----------
Oxford BioMedica PLC, down 1.3% at 334.65p, 12-month range 276.6p-575p. The gene and cell therapy group expands its licence and supply deal with clinical-stage biotechnology company Cabaletta Bio Inc. Under expanded agreement, will grant a non-exclusive licence to Cabaletta under Oxford Bio's LentiVector platform IP for their CAR-T programme, CABA-201. Says Cabaletta has received two IND clearances for CABA-201, and is intending to launch a phase 1/2 clinical trial for patients with systemic lupus erythematosus and lupus nephritis immune diseases, as well as a separate trial for myositis. "Oxford Biomedica will receive an undisclosed upfront payment, as well as additional payments relating to the development and manufacture of lentiviral vectors for use in clinical trials," it says. Will also receive milestone payments and an undisclosed royalty on net sales of products that use its LentiVector platform.
----------
By Elizabeth Winter, Alliance News senior markets reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.